Arcscan's Insight 100 Ophthalmic Ultrasound Imaging System Approved in China

ArcScan announced that the ArcScan Insight 100 has received National Medical Products Administration (NMPA) approval in China.

The Insight 100 is designed to allow eye surgeons to more accurately determine the appropriate sizing of phakic IOLs for placement behind the iris for treatment of myopia. According to Market Scope, phakic IOL procedures will surpass 780,000 procedures globally in 2024, with a projected growth rate of 8.8 percent from 2024 to 2029.

“We believe the ArcScan Insight 100 will help eyecare surgeons in China to better address the myopia epidemic which is predicted to affect 5 billion people globally by 2050, according to the journal Ophthalmology,” Andrew Levien, ArcScan CEO, said in a company news release. “Surpassing the limitations of optical coherence tomography (OCT), our ultrasound solution provides comprehensive visualization of the anterior segment to help surgeons identify anatomical artifacts that could contribute to substandard post-surgical outcomes.”

“The Insight 100 has significantly improved outcomes for my patients,” said Robert Lin, MD, founder and CEO, IQ Laser Vision, California. “The most precise epithelial mapping technology with accuracy down to 1 um allows me to better assess the risk of keratoconus. Better visualization into the anterior segment and reproducible, easy and precise measurement of the sulcus, where the posterior phakic IOL (EVO ICL, Staar and pICL) allows better sizing of the pIOL to reduce potential risks of lens rotation, glaucoma and cataracts.”

In addition to NMPA certification, The Arcscan Insight 100 has FDA clearance and CE Mark approval. For more information, click here.